Benitec Biopharma: ASX Spotlight Series (NY, Mar 2015)

Company Presentations

by Carolyn Herbert

Benitec Biopharma Limited (ASX:BLT) Chief Business Officer Carl Stubbings presents at ASX Spotlight Series in New York. 
The biotechnology company’s presentation is titled, “Gene Silencing: A quiet revolution in healthcare”. 
Mr Stubbings provides a financial snapshot and investment case for Benitec Biopharma while outlining the group’s operations. 
Summarising the presentation Mr Stubbings says, “We are developing a technology... with our lead indication TT 034 being a disruptive technology in what we believe will remain a significant market. 
Potentially we can provide a cure for a wide range of diseases; we have over 100 patents around the technology and specific diseases themselves. 
We have an extensive pipeline of programs, as I’ve said previously, any one of which could be a company maker.” 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.